Daniel M. Junius's most recent trade in Idexx Laboratories, Inc. was a trade of 2,683 Common Stock done at an average price of $506.4 . Disclosure was reported to the exchange on May 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 506.41 per share. | 13 May 2025 | 2,683 | 3,304 (0%) | 0% | 506.4 | 1,358,697 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 245.79 per share. | 13 May 2025 | 1,404 | 4,708 (0%) | 0% | 245.8 | 345,089 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 1,404 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 1,279 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 283.59 per share. | 13 May 2025 | 1,279 | 5,987 (0%) | 0% | 283.6 | 362,712 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 600 | 600 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 262 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 262 | 3,304 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 257 | 257 | - | - | Restricted Stock Unit | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 609 | 609 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 262 | 262 | - | - | Restricted Stock Unit | |
| GlycoMimetics Inc | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| GlycoMimetics Inc | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 29 Mar 2024 | 5,209 | 98,459 (0%) | 0% | 3 | 15,627 | Common Stock |
| Idexx Laboratories, Inc. | Junius Daniel M. | Director | Grant, award, or other acquisition of securities at price $ 521.00 per share. | 30 Jan 2024 | 14 | 3,042 (0%) | 0% | 521 | 7,294 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 552.79 per share. | 28 Jul 2023 | 14 | 3,009 (0%) | 0% | 552.8 | 7,739 | Common Stock |
| GlycoMimetics Inc | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 645 | 645 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 257 | 601 | - | - | Deferred Stock Unit | |
| GlycoMimetics Inc | Daniel M. Junius | Director | Purchase of securities on an exchange or from another person at price $ 1.56 per share. | 10 May 2023 | 30,000 | 93,250 (0%) | 0% | 1.6 | 46,800 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 492.15 per share. | 28 Apr 2023 | 13 | 2,995 (0%) | 0% | 492.2 | 6,398 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 511.68 per share. | 16 Feb 2023 | 2,187 | 2,982 (0%) | 0% | 511.7 | 1,119,044 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 2,187 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.62 per share. | 16 Feb 2023 | 2,187 | 5,169 (0%) | 0% | 206.6 | 451,878 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 482.93 per share. | 30 Jan 2023 | 14 | 2,982 (0%) | 0% | 482.9 | 6,761 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 424.91 per share. | 05 Dec 2022 | 3,046 | 2,968 (0%) | 0% | 424.9 | 1,294,276 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 160.28 per share. | 05 Dec 2022 | 3,046 | 6,014 (0%) | 0% | 160.3 | 488,213 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Dec 2022 | 3,046 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| GlycoMimetics Inc | Daniel M. Junius | Director | Purchase of securities on an exchange or from another person at price $ 1.87 per share. | 17 Nov 2022 | 20,000 | 63,250 (0%) | 0% | 1.9 | 37,400 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 364.28 per share. | 28 Oct 2022 | 18 | 2,968 (0%) | 0% | 364.3 | 6,557 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 399.19 per share. | 29 Jul 2022 | 16 | 2,950 (0%) | 0% | 399.2 | 6,387 | Common Stock |
| GlycoMimetics Inc | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 945 | 945 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 344 | 344 | - | - | Deferred Stock Unit | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 430.47 per share. | 29 Apr 2022 | 15 | 2,934 (0%) | 0% | 430.5 | 6,457 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 489.08 per share. | 28 Jan 2022 | 13 | 2,919 (0%) | 0% | 489.1 | 6,358 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 666.10 per share. | 29 Oct 2021 | 10 | 2,906 (0%) | 0% | 666.1 | 6,661 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 10 Aug 2021 | 2,402 | 5,298 (0%) | 0% | 85 | 204,170 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 679.58 per share. | 10 Aug 2021 | 2,402 | 2,896 (0%) | 0% | 679.6 | 1,632,355 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 2,402 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 678.50 per share. | 30 Jul 2021 | 10 | 2,896 (0%) | 0% | 678.5 | 6,785 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 539.57 per share. | 21 May 2021 | 2,500 | 2,886 (0%) | 0% | 539.6 | 1,348,918 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2021 | 2,500 | 2,402 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 21 May 2021 | 2,500 | 5,386 (0%) | 0% | 85 | 212,500 | Common Stock |
| GlycoMimetics Inc | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| GlycoMimetics Inc | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2021 | 5,250 | 43,250 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 723 | 723 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 224 | 3,387 | - | - | Deferred Stock Unit | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 549.00 per share. | 30 Apr 2021 | 11 | 2,886 (0%) | 0% | 549 | 6,039 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 538.57 per share. | 22 Feb 2021 | 1,888 | 2,875 (0%) | 0% | 538.6 | 1,016,815 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 1,000 | 4,902 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 22 Feb 2021 | 1,000 | 4,773 (0%) | 0% | 85 | 85,000 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 898 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 22 Feb 2021 | 898 | 3,773 (0%) | 0% | 79.5 | 71,427 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 539.20 per share. | 22 Feb 2021 | 10 | 4,763 (0%) | 0% | 539.2 | 5,392 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 478.69 per share. | 29 Jan 2021 | 13 | 2,875 (0%) | 0% | 478.7 | 6,223 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 424.80 per share. | 30 Oct 2020 | 15 | 2,862 (0%) | 0% | 424.8 | 6,372 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Sale of securities on an exchange or to another person at price $ 382.61 per share. | 20 Aug 2020 | 3,722 | 2,847 (0%) | 0% | 382.6 | 1,424,063 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.95 per share. | 20 Aug 2020 | 3,722 | 6,569 (0%) | 0% | 64.0 | 238,022 | Common Stock |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 3,722 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories, Inc. | Daniel M. Junius | Director | Grant, award, or other acquisition of securities at price $ 371.08 per share. | 30 Jul 2020 | 13 | 2,847 (0%) | 0% | 371.1 | 4,824 | Common Stock |